{"transactions":[{"id":728060,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T20:04:28.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":35,"value":87500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares sold in this transaction were sold to cover applicable tax withholding obligations incurred upon the vesting of restricted stock units and were not sold for investment purposes."}],"balance_after":10125,"source":{"system":"sec-edgar","filing":"0000905148-26-003076","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826003076/form4.xml","form_type":"4"}},{"id":760610,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-28T20:19:05.000Z","date":"2026-05-26","kind":"sale","planned":true,"acquired":false,"shares":2500,"price":29.17,"value":72925.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 7, 2025."}],"balance_after":12625,"source":{"system":"sec-edgar","filing":"0000905148-26-002724","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002724/form4.xml","form_type":"4"}},{"id":772912,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-20T00:48:13.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":5750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":15125,"source":{"system":"sec-edgar","filing":"0000905148-26-002529","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514826002529/form4.xml","form_type":"4"}},{"id":867112,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2026-03-03T23:47:23.000Z","date":"2026-01-12","kind":"grant","planned":false,"acquired":true,"shares":54876,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date."}],"balance_after":54876,"derivative":{"exercise_price":0.98,"expiration_date":"2036-01-12","underlying":"Common Stock","underlying_shares":54876},"source":{"system":"sec-edgar","filing":"0001140361-26-007641","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000114036126007641/form4.xml","form_type":"4"}},{"id":1114907,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2025-06-11T22:00:36.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":22700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date."}],"balance_after":22700,"derivative":{"exercise_price":1.75,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":22700},"source":{"system":"sec-edgar","filing":"0001140361-25-022225","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000114036125022225/form4.xml","form_type":"4"}},{"id":1132351,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-28T21:27:31.000Z","date":"2025-05-23","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":3000,"derivative":{"exercise_price":18.95,"expiration_date":"2035-05-23","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0000905148-25-001935","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825001935/form4.xml","form_type":"4"}},{"id":1132350,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-28T21:27:31.000Z","date":"2025-05-23","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024."}],"balance_after":9375,"source":{"system":"sec-edgar","filing":"0000905148-25-001935","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514825001935/form4.xml","form_type":"4"}},{"id":1469500,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-06-25T20:05:06.000Z","date":"2024-06-24","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date."}],"balance_after":9000,"derivative":{"exercise_price":2.86,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001140361-24-031289","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000114036124031289/form4.xml","form_type":"4"}},{"id":1499438,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-29T23:19:26.000Z","date":"2024-05-25","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":0.9075,"expiration_date":"2034-05-25","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000905148-24-001651","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824001651/form4.xml","form_type":"4"}},{"id":1499437,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-05-29T23:19:26.000Z","date":"2024-05-25","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":68750,"source":{"system":"sec-edgar","filing":"0000905148-24-001651","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000090514824001651/form4.xml","form_type":"4"}},{"id":1828637,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2023-07-17T21:28:21.000Z","date":"2023-07-14","kind":"grant","planned":false,"acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date."}],"balance_after":9000,"derivative":{"exercise_price":5.13,"expiration_date":"2033-07-14","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001140361-23-034836","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000114036123034836/form4.xml","form_type":"4"}},{"id":1831086,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-12T22:45:31.000Z","date":"2023-05-26","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":30000,"derivative":{"exercise_price":1.32,"expiration_date":"2033-05-26","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001140361-23-034284","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036123034284/form4.xml","form_type":"4"}},{"id":1831085,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-07-12T22:45:31.000Z","date":"2023-05-26","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":43750,"source":{"system":"sec-edgar","filing":"0001140361-23-034284","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036123034284/form4.xml","form_type":"4"}},{"id":2219372,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-29T20:15:35.000Z","date":"2022-06-28","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date."}],"balance_after":9000,"derivative":{"exercise_price":3.9,"expiration_date":"2032-06-28","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001140361-22-024466","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000114036122024466/form4.xml","form_type":"4"}},{"id":2260445,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-23T21:50:07.000Z","date":"2022-05-20","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares vest monthly over one (1) year from the date of grant subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":22500,"derivative":{"exercise_price":2.01,"expiration_date":"2032-05-20","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001140361-22-020303","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036122020303/form4.xml","form_type":"4"}},{"id":2260444,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-05-23T21:50:07.000Z","date":"2022-05-20","kind":"grant","acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors."}],"balance_after":18750,"source":{"system":"sec-edgar","filing":"0001140361-22-020303","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000114036122020303/form4.xml","form_type":"4"}},{"id":2443944,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2022-01-05T21:33:56.000Z","date":"2022-01-03","kind":"exercise","acquired":false,"shares":7100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":28400},"source":{"system":"sec-edgar","filing":"0001209191-22-001712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919122001712/doc4.xml","form_type":"4"}},{"id":2443943,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Unit","published_at":"2022-01-05T21:33:56.000Z","date":"2022-01-03","kind":"exercise","acquired":false,"shares":6638,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":19914},"source":{"system":"sec-edgar","filing":"0001209191-22-001712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919122001712/doc4.xml","form_type":"4"}},{"id":2443942,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2022-01-05T21:33:56.000Z","date":"2022-01-03","kind":"exercise","acquired":false,"shares":27905,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":34350},"source":{"system":"sec-edgar","filing":"0001209191-22-001712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919122001712/doc4.xml","form_type":"4"}},{"id":2443941,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2022-01-05T21:33:56.000Z","date":"2022-01-03","kind":"exercise","acquired":false,"shares":3875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of restricted stock units that were accelerated by mutual agreement between the Reporting Person and the Issuer. The balance of unvested restricted stock units, if any, were forfeited."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3875},"source":{"system":"sec-edgar","filing":"0001209191-22-001712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919122001712/doc4.xml","form_type":"4"}},{"id":2443940,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-01-05T21:33:56.000Z","date":"2022-01-03","kind":"exercise","acquired":true,"shares":7100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":160214,"source":{"system":"sec-edgar","filing":"0001209191-22-001712","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919122001712/doc4.xml","form_type":"4"}},{"id":2443939,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-01-05T21:33:56.000Z","date":"2022-01-03","kind":"exercise","acquired":true,"shares":6638,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":153114,"source":{"system":"sec-edgar","filing":"0001209191-22-001712","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919122001712/doc4.xml","form_type":"4"}},{"id":2443938,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-01-05T21:33:56.000Z","date":"2022-01-03","kind":"exercise","acquired":true,"shares":27905,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":146476,"source":{"system":"sec-edgar","filing":"0001209191-22-001712","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919122001712/doc4.xml","form_type":"4"}},{"id":2443937,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2022-01-05T21:33:56.000Z","date":"2022-01-03","kind":"exercise","acquired":true,"shares":3875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":118571,"source":{"system":"sec-edgar","filing":"0001209191-22-001712","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919122001712/doc4.xml","form_type":"4"}},{"id":2468119,"issuer":{"id":2423,"kind":"organization","name":"RIGEL PHARMACEUTICALS INC","symbol":"RIGL"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-17T21:22:10.000Z","date":"2021-12-16","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest in equal monthly installments over the shorter of three years from the date of grant or the period beginning on the date the Reporting Person was appointed to the Company's Board of Directors and ending on the date of the annual meeting at which the Reporting Person is first considered for election by the stockholders, provided that the Reporting Person continues to provide service."}],"balance_after":120000,"derivative":{"exercise_price":2.44,"expiration_date":"2031-12-16","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001567619-21-022261","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1034842/000156761921022261/doc1.xml","form_type":"4"}},{"id":2500785,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-11-22T21:03:02.000Z","date":"2021-03-11","kind":"gift","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":114696,"source":{"system":"sec-edgar","filing":"0001209191-21-066084","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121066084/doc4.xml","form_type":"4"}},{"id":2663803,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-17T23:09:59.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Stock Option will vest in full and become fully exercisable on June 17, 2022."}],"balance_after":9000,"derivative":{"exercise_price":9.95,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001140361-21-021497","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000114036121021497/form4.xml","form_type":"4"}},{"id":2663802,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-06-17T23:09:59.000Z","date":"2021-06-15","kind":"purchase","acquired":true,"shares":11764,"price":8.5,"value":99994.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock purchased by the Reporting Person at the public offering price in connection with the Issuer's firm commitment underwritten public offering of common stock, which closed on June 17, 2021, and such shares of common stock are subject to a lock up agreement between the Reporting Person and Cantor Fitzgerald & Co., pursuant to which the shares cannot be sold for 90 days following June 15, 2021."}],"balance_after":11764,"source":{"system":"sec-edgar","filing":"0001140361-21-021497","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000114036121021497/form4.xml","form_type":"4"}},{"id":2680953,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-06-04T23:52:37.000Z","date":"2021-06-03","kind":"sale","acquired":false,"shares":9492,"price":21.9575,"value":208420.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.57 to $22.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":122196,"source":{"system":"sec-edgar","filing":"0001209191-21-038442","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121038442/doc4.xml","form_type":"4"}},{"id":2686601,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2021-06-03T01:47:22.000Z","date":"2021-06-01","kind":"exercise","acquired":false,"shares":33189,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F10","text":"The shares underlying these restricted stock units vested in two equal annual installments beginning on June 1, 2020."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":33189},"source":{"system":"sec-edgar","filing":"0001209191-21-037482","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121037482/doc4.xml","form_type":"4"}},{"id":2686600,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-06-03T01:47:22.000Z","date":"2021-06-02","kind":"sale","acquired":false,"shares":2387,"price":22.3112,"value":53256.8344,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.07 to $22.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":131688,"source":{"system":"sec-edgar","filing":"0001209191-21-037482","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121037482/doc4.xml","form_type":"4"}},{"id":2686599,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-06-03T01:47:22.000Z","date":"2021-06-02","kind":"sale","acquired":false,"shares":12732,"price":21.5066,"value":273822.0312,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on June 1, 2021 pursuant to preexisting sell-to-cover elections."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.06 to $22.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":134075,"source":{"system":"sec-edgar","filing":"0001209191-21-037482","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121037482/doc4.xml","form_type":"4"}},{"id":2686598,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-06-03T01:47:22.000Z","date":"2021-06-02","kind":"sale","acquired":false,"shares":2517,"price":22.3175,"value":56173.1475,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.06 to $22.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":146807,"source":{"system":"sec-edgar","filing":"0001209191-21-037482","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121037482/doc4.xml","form_type":"4"}},{"id":2686597,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-06-03T01:47:22.000Z","date":"2021-06-02","kind":"sale","acquired":false,"shares":12483,"price":21.5022,"value":268411.9626,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.03 to $22.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":149324,"source":{"system":"sec-edgar","filing":"0001209191-21-037482","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121037482/doc4.xml","form_type":"4"}},{"id":2686596,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-06-03T01:47:22.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":5254,"price":23.5728,"value":123851.4912,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.27 to $23.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":161807,"source":{"system":"sec-edgar","filing":"0001209191-21-037482","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121037482/doc4.xml","form_type":"4"}},{"id":2686595,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-06-03T01:47:22.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":9746,"price":22.7219,"value":221447.6374,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.25 to $23.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":167061,"source":{"system":"sec-edgar","filing":"0001209191-21-037482","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121037482/doc4.xml","form_type":"4"}},{"id":2686594,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-06-03T01:47:22.000Z","date":"2021-06-01","kind":"exercise","acquired":true,"shares":33189,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":176807,"source":{"system":"sec-edgar","filing":"0001209191-21-037482","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121037482/doc4.xml","form_type":"4"}},{"id":2723173,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-05-07T22:28:02.000Z","date":"2021-05-07","kind":"exercise","acquired":false,"shares":5416,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":10.66,"expiration_date":"2025-08-31","underlying":"Common Stock","underlying_shares":5416},"source":{"system":"sec-edgar","filing":"0001209191-21-031038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121031038/doc4.xml","form_type":"4"}},{"id":2723172,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-05-07T22:28:02.000Z","date":"2021-05-06","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option is fully vested."}],"balance_after":5416,"derivative":{"exercise_price":10.66,"expiration_date":"2025-08-31","underlying":"Common Stock","underlying_shares":20416},"source":{"system":"sec-edgar","filing":"0001209191-21-031038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121031038/doc4.xml","form_type":"4"}},{"id":2723171,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-07T22:28:02.000Z","date":"2021-05-07","kind":"sale","acquired":false,"shares":2100,"price":23.9886,"value":50376.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.83 to $24.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":143618,"source":{"system":"sec-edgar","filing":"0001209191-21-031038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121031038/doc4.xml","form_type":"4"}},{"id":2723170,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-07T22:28:02.000Z","date":"2021-05-07","kind":"sale","acquired":false,"shares":3316,"price":23.2255,"value":77015.758,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.83 to $23.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":145718,"source":{"system":"sec-edgar","filing":"0001209191-21-031038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121031038/doc4.xml","form_type":"4"}},{"id":2723169,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-07T22:28:02.000Z","date":"2021-05-07","kind":"exercise","acquired":true,"shares":5416,"price":10.66,"value":57734.56,"ownership":{"direct":true},"balance_after":149034,"source":{"system":"sec-edgar","filing":"0001209191-21-031038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121031038/doc4.xml","form_type":"4"}},{"id":2723168,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-07T22:28:02.000Z","date":"2021-05-06","kind":"sale","acquired":false,"shares":3102,"price":23.8606,"value":74015.5812,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.79 to $23.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":143618,"source":{"system":"sec-edgar","filing":"0001209191-21-031038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121031038/doc4.xml","form_type":"4"}},{"id":2723167,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-07T22:28:02.000Z","date":"2021-05-06","kind":"sale","acquired":false,"shares":11898,"price":23.318,"value":277437.564,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $22.79 to $23.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":146720,"source":{"system":"sec-edgar","filing":"0001209191-21-031038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121031038/doc4.xml","form_type":"4"}},{"id":2723166,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-07T22:28:02.000Z","date":"2021-05-06","kind":"exercise","acquired":true,"shares":15000,"price":10.66,"value":159900.0,"ownership":{"direct":true},"balance_after":158618,"source":{"system":"sec-edgar","filing":"0001209191-21-031038","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121031038/doc4.xml","form_type":"4"}},{"id":2727279,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-05-06T00:04:13.000Z","date":"2021-05-05","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option is fully vested."}],"balance_after":20416,"derivative":{"exercise_price":10.66,"expiration_date":"2025-08-31","underlying":"Common Stock","underlying_shares":35416},"source":{"system":"sec-edgar","filing":"0001209191-21-030491","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121030491/doc4.xml","form_type":"4"}},{"id":2727278,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-05-06T00:04:13.000Z","date":"2021-05-04","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option is fully vested."}],"balance_after":35416,"derivative":{"exercise_price":10.66,"expiration_date":"2025-08-31","underlying":"Common Stock","underlying_shares":50416},"source":{"system":"sec-edgar","filing":"0001209191-21-030491","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121030491/doc4.xml","form_type":"4"}},{"id":2727277,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-05-06T00:04:13.000Z","date":"2021-05-03","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The option is fully vested."}],"balance_after":50416,"derivative":{"exercise_price":10.66,"expiration_date":"2025-08-31","underlying":"Common Stock","underlying_shares":65416},"source":{"system":"sec-edgar","filing":"0001209191-21-030491","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121030491/doc4.xml","form_type":"4"}},{"id":2727276,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-06T00:04:13.000Z","date":"2021-05-05","kind":"sale","acquired":false,"shares":498,"price":24.3559,"value":12129.2382,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.33 to $24.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":143618,"source":{"system":"sec-edgar","filing":"0001209191-21-030491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121030491/doc4.xml","form_type":"4"}},{"id":2727275,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-06T00:04:13.000Z","date":"2021-05-05","kind":"sale","acquired":false,"shares":14502,"price":23.968,"value":347583.936,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.32 to $24.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":144116,"source":{"system":"sec-edgar","filing":"0001209191-21-030491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121030491/doc4.xml","form_type":"4"}},{"id":2727274,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-06T00:04:13.000Z","date":"2021-05-05","kind":"exercise","acquired":true,"shares":15000,"price":10.66,"value":159900.0,"ownership":{"direct":true},"balance_after":158618,"source":{"system":"sec-edgar","filing":"0001209191-21-030491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121030491/doc4.xml","form_type":"4"}},{"id":2727273,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-06T00:04:13.000Z","date":"2021-05-04","kind":"sale","acquired":false,"shares":1279,"price":24.4691,"value":31295.9789,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.19 to $24.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":143618,"source":{"system":"sec-edgar","filing":"0001209191-21-030491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121030491/doc4.xml","form_type":"4"}},{"id":2727272,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-06T00:04:13.000Z","date":"2021-05-04","kind":"sale","acquired":false,"shares":13721,"price":23.6055,"value":323891.0655,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.17 to $24.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":144897,"source":{"system":"sec-edgar","filing":"0001209191-21-030491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121030491/doc4.xml","form_type":"4"}},{"id":2727271,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-06T00:04:13.000Z","date":"2021-05-04","kind":"exercise","acquired":true,"shares":15000,"price":10.66,"value":159900.0,"ownership":{"direct":true},"balance_after":158618,"source":{"system":"sec-edgar","filing":"0001209191-21-030491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121030491/doc4.xml","form_type":"4"}},{"id":2727270,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-06T00:04:13.000Z","date":"2021-05-03","kind":"sale","acquired":false,"shares":4339,"price":24.9075,"value":108073.6425,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $24.82 to $24.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":143618,"source":{"system":"sec-edgar","filing":"0001209191-21-030491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121030491/doc4.xml","form_type":"4"}},{"id":2727269,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-06T00:04:13.000Z","date":"2021-05-03","kind":"sale","acquired":false,"shares":10661,"price":24.4578,"value":260744.6058,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 10, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $23.82 to $24.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":147957,"source":{"system":"sec-edgar","filing":"0001209191-21-030491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121030491/doc4.xml","form_type":"4"}},{"id":2727268,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-05-06T00:04:13.000Z","date":"2021-05-03","kind":"exercise","acquired":true,"shares":15000,"price":10.66,"value":159900.0,"ownership":{"direct":true},"balance_after":158618,"source":{"system":"sec-edgar","filing":"0001209191-21-030491","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121030491/doc4.xml","form_type":"4"}},{"id":2813602,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted stock units","published_at":"2021-03-04T01:39:12.000Z","date":"2021-03-02","kind":"exercise","acquired":false,"shares":6637,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":19914,"derivative":{"underlying":"Common Stock","underlying_shares":6637},"source":{"system":"sec-edgar","filing":"0001209191-21-017544","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121017544/doc4.xml","form_type":"4"}},{"id":2813601,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted stock units","published_at":"2021-03-04T01:39:12.000Z","date":"2021-03-01","kind":"exercise","acquired":false,"shares":17175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":34350,"derivative":{"underlying":"Common Stock","underlying_shares":17175},"source":{"system":"sec-edgar","filing":"0001209191-21-017544","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121017544/doc4.xml","form_type":"4"}},{"id":2813600,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted stock units","published_at":"2021-03-04T01:39:12.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":28400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2022, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":28400,"derivative":{"underlying":"Common Stock","underlying_shares":28400},"source":{"system":"sec-edgar","filing":"0001209191-21-017544","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121017544/doc4.xml","form_type":"4"}},{"id":2813599,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-03-04T01:39:12.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":99500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date."}],"balance_after":99500,"derivative":{"exercise_price":24.06,"expiration_date":"2031-02-28","underlying":"Common Stock","underlying_shares":99500},"source":{"system":"sec-edgar","filing":"0001209191-21-017544","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121017544/doc4.xml","form_type":"4"}},{"id":2813598,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:39:12.000Z","date":"2021-03-02","kind":"tax_withholding","acquired":false,"shares":1906,"price":23.25,"value":44314.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":143618,"source":{"system":"sec-edgar","filing":"0001209191-21-017544","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121017544/doc4.xml","form_type":"4"}},{"id":2813597,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:39:12.000Z","date":"2021-03-02","kind":"exercise","acquired":true,"shares":6637,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":145524,"source":{"system":"sec-edgar","filing":"0001209191-21-017544","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121017544/doc4.xml","form_type":"4"}},{"id":2813596,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:39:12.000Z","date":"2021-03-01","kind":"tax_withholding","acquired":false,"shares":4934,"price":24.06,"value":118712.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":138887,"source":{"system":"sec-edgar","filing":"0001209191-21-017544","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121017544/doc4.xml","form_type":"4"}},{"id":2813595,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:39:12.000Z","date":"2021-03-01","kind":"exercise","acquired":true,"shares":17175,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":143821,"source":{"system":"sec-edgar","filing":"0001209191-21-017544","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121017544/doc4.xml","form_type":"4"}},{"id":2881894,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2021-02-03T22:26:46.000Z","date":"2021-02-01","kind":"exercise","acquired":false,"shares":3875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":3875,"derivative":{"underlying":"Common Stock","underlying_shares":3875},"source":{"system":"sec-edgar","filing":"0001209191-21-007372","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121007372/doc4.xml","form_type":"4"}},{"id":2881893,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-02-03T22:26:46.000Z","date":"2021-02-01","kind":"tax_withholding","acquired":false,"shares":1318,"price":21.35,"value":28139.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":126646,"source":{"system":"sec-edgar","filing":"0001209191-21-007372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121007372/doc4.xml","form_type":"4"}},{"id":2881892,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2021-02-03T22:26:46.000Z","date":"2021-02-01","kind":"exercise","acquired":true,"shares":3875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":127964,"source":{"system":"sec-edgar","filing":"0001209191-21-007372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919121007372/doc4.xml","form_type":"4"}},{"id":2940213,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2020-12-17T22:06:23.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":1734,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 15, 2016, the reporting person was granted 13,866 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vested in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On December 15, 2016, the reporting person was granted 13,866 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vested in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1734},"source":{"system":"sec-edgar","filing":"0001209191-20-064122","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919120064122/doc4.xml","form_type":"4"}},{"id":2940212,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-12-17T22:06:23.000Z","date":"2020-12-15","kind":"tax_withholding","acquired":false,"shares":498,"price":4.59,"value":2285.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":124089,"source":{"system":"sec-edgar","filing":"0001209191-20-064122","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919120064122/doc4.xml","form_type":"4"}},{"id":2940211,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-12-17T22:06:23.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":1734,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":124587,"source":{"system":"sec-edgar","filing":"0001209191-20-064122","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919120064122/doc4.xml","form_type":"4"}},{"id":3099793,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-25T22:38:55.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":3033,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One third of the shares underlying the option shall vest upon each of the first, second, and third anniversaries of the date of grant, such that the option will be fully vested on June 23, 2023."}],"balance_after":3033,"derivative":{"exercise_price":1.45,"expiration_date":"2030-06-23","underlying":"Common Stock","underlying_shares":3033},"source":{"system":"sec-edgar","filing":"0001140361-20-014769","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000114036120014769/form4.xml","form_type":"4"}},{"id":3124171,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted stock units","published_at":"2020-06-03T20:42:24.000Z","date":"2020-06-01","kind":"exercise","acquired":false,"shares":33188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":33189,"derivative":{"underlying":"Common Stock","underlying_shares":33188},"source":{"system":"sec-edgar","filing":"0001209191-20-034060","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919120034060/doc4.xml","form_type":"4"}},{"id":3124170,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-06-03T20:42:24.000Z","date":"2020-06-01","kind":"tax_withholding","acquired":false,"shares":9534,"price":1.32,"value":12584.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":122853,"source":{"system":"sec-edgar","filing":"0001209191-20-034060","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919120034060/doc4.xml","form_type":"4"}},{"id":3124169,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-06-03T20:42:24.000Z","date":"2020-06-01","kind":"exercise","acquired":true,"shares":33188,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":132387,"source":{"system":"sec-edgar","filing":"0001209191-20-034060","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919120034060/doc4.xml","form_type":"4"}},{"id":3227570,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted stock units","published_at":"2020-03-04T21:22:40.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":26551,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 2, 2021, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":26551,"derivative":{"underlying":"Common Stock","underlying_shares":26551},"source":{"system":"sec-edgar","filing":"0001209191-20-016073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919120016073/doc4.xml","form_type":"4"}},{"id":3227569,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted stock units","published_at":"2020-03-04T21:22:40.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":66377,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The shares underlying these restricted stock units vest in two equal annual installments beginning on June 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":66377,"derivative":{"underlying":"Common Stock","underlying_shares":66377},"source":{"system":"sec-edgar","filing":"0001209191-20-016073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919120016073/doc4.xml","form_type":"4"}},{"id":3227568,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-03-04T21:22:40.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":92928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable with respect to 25% of the shares subject to the option vesting on each of the first, second, third and fourth anniversaries of the grant date, subject to Reporting Person's continuous service through each such date."}],"balance_after":92928,"derivative":{"exercise_price":1.26,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":92928},"source":{"system":"sec-edgar","filing":"0001209191-20-016073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919120016073/doc4.xml","form_type":"4"}},{"id":3227567,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted stock units","published_at":"2020-03-04T21:22:40.000Z","date":"2020-03-02","kind":"exercise","acquired":false,"shares":17175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":51525,"derivative":{"underlying":"Common Stock","underlying_shares":17175},"source":{"system":"sec-edgar","filing":"0001209191-20-016073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919120016073/doc4.xml","form_type":"4"}},{"id":3227566,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-03-04T21:22:40.000Z","date":"2020-03-02","kind":"tax_withholding","acquired":false,"shares":4779,"price":1.26,"value":6021.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":99199,"source":{"system":"sec-edgar","filing":"0001209191-20-016073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919120016073/doc4.xml","form_type":"4"}},{"id":3227565,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-03-04T21:22:40.000Z","date":"2020-03-02","kind":"exercise","acquired":true,"shares":17175,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."}],"balance_after":103978,"source":{"system":"sec-edgar","filing":"0001209191-20-016073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919120016073/doc4.xml","form_type":"4"}},{"id":3253001,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-24T21:30:53.000Z","date":"2020-02-21","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third (1/3) of the shares underlying the option shall vest upon each of the first, second and third anniversaries of the date of grant, such that the option will be fully vested on February 21, 2023."}],"balance_after":9000,"derivative":{"exercise_price":1.31,"expiration_date":"2030-02-21","underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001140361-20-003908","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000114036120003908/form4.xml","form_type":"4"}},{"id":3291809,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2020-02-05T00:11:06.000Z","date":"2020-02-03","kind":"exercise","acquired":false,"shares":3875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":7750,"derivative":{"underlying":"Common Stock","underlying_shares":3875},"source":{"system":"sec-edgar","filing":"0001209191-20-006666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919120006666/doc4.xml","form_type":"4"}},{"id":3291808,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-02-05T00:11:06.000Z","date":"2020-02-03","kind":"tax_withholding","acquired":false,"shares":1318,"price":1.28,"value":1687.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":86803,"source":{"system":"sec-edgar","filing":"0001209191-20-006666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919120006666/doc4.xml","form_type":"4"}},{"id":3291807,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2020-02-05T00:11:06.000Z","date":"2020-02-03","kind":"exercise","acquired":true,"shares":3875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":88121,"source":{"system":"sec-edgar","filing":"0001209191-20-006666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919120006666/doc4.xml","form_type":"4"}},{"id":3333881,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2019-12-20T21:17:37.000Z","date":"2019-12-18","kind":"exercise","acquired":false,"shares":1075,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 18, 2015, the reporting person was granted 4,300 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On December 18, 2015, the reporting person was granted 4,300 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1075},"source":{"system":"sec-edgar","filing":"0001209191-19-061536","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919119061536/doc4.xml","form_type":"4"}},{"id":3333880,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-12-20T21:17:37.000Z","date":"2019-12-18","kind":"tax_withholding","acquired":false,"shares":277,"price":1.81,"value":501.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":84246,"source":{"system":"sec-edgar","filing":"0001209191-19-061536","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919119061536/doc4.xml","form_type":"4"}},{"id":3333879,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-12-20T21:17:37.000Z","date":"2019-12-18","kind":"exercise","acquired":true,"shares":1075,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":84523,"source":{"system":"sec-edgar","filing":"0001209191-19-061536","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919119061536/doc4.xml","form_type":"4"}},{"id":3336892,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2019-12-18T16:00:22.000Z","date":"2019-12-16","kind":"exercise","acquired":false,"shares":1733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 15, 2016, the reporting person was granted 13,866 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On December 15, 2016, the reporting person was granted 13,866 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":1734,"derivative":{"underlying":"Common Stock","underlying_shares":1733},"source":{"system":"sec-edgar","filing":"0001209191-19-061067","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919119061067/doc4.xml","form_type":"4"}},{"id":3336891,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-12-18T16:00:22.000Z","date":"2019-12-16","kind":"tax_withholding","acquired":false,"shares":497,"price":1.8,"value":894.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":83448,"source":{"system":"sec-edgar","filing":"0001209191-19-061067","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919119061067/doc4.xml","form_type":"4"}},{"id":3336890,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-12-18T16:00:22.000Z","date":"2019-12-16","kind":"exercise","acquired":true,"shares":1733,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":83945,"source":{"system":"sec-edgar","filing":"0001209191-19-061067","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919119061067/doc4.xml","form_type":"4"}},{"id":3619148,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted stock units","published_at":"2019-03-04T23:13:17.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":68700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on March 1, 2020, subject to the Reporting Person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":68700,"derivative":{"underlying":"Common Stock","underlying_shares":68700},"source":{"system":"sec-edgar","filing":"0001209191-19-015898","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919119015898/doc4.xml","form_type":"4"}},{"id":3674399,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2019-02-05T23:29:06.000Z","date":"2019-02-01","kind":"exercise","acquired":false,"shares":3875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":11625,"derivative":{"underlying":"Common Stock","underlying_shares":3875},"source":{"system":"sec-edgar","filing":"0001209191-19-007485","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919119007485/doc4.xml","form_type":"4"}},{"id":3674398,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-02-05T23:29:06.000Z","date":"2019-02-01","kind":"tax_withholding","acquired":false,"shares":1308,"price":6.96,"value":9103.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":82212,"source":{"system":"sec-edgar","filing":"0001209191-19-007485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919119007485/doc4.xml","form_type":"4"}},{"id":3674397,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2019-02-05T23:29:06.000Z","date":"2019-02-01","kind":"exercise","acquired":true,"shares":3875,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":83520,"source":{"system":"sec-edgar","filing":"0001209191-19-007485","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919119007485/doc4.xml","form_type":"4"}},{"id":3723353,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2018-12-21T02:59:33.000Z","date":"2018-12-18","kind":"exercise","acquired":false,"shares":1075,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 18, 2015, the reporting person was granted 4,300 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On December 18, 2015, the reporting person was granted 4,300 restricted stock units, vesting in four equal annual installments beginning on December 18, 2016, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":1075,"derivative":{"underlying":"Common Stock","underlying_shares":1075},"source":{"system":"sec-edgar","filing":"0001209191-18-063795","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919118063795/doc4.xml","form_type":"4"}},{"id":3723352,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2018-12-21T02:59:33.000Z","date":"2018-12-18","kind":"tax_withholding","acquired":false,"shares":306,"price":6.3,"value":1927.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":79645,"source":{"system":"sec-edgar","filing":"0001209191-18-063795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919118063795/doc4.xml","form_type":"4"}},{"id":3723351,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2018-12-21T02:59:33.000Z","date":"2018-12-18","kind":"exercise","acquired":true,"shares":1075,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."}],"balance_after":79951,"source":{"system":"sec-edgar","filing":"0001209191-18-063795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919118063795/doc4.xml","form_type":"4"}},{"id":3727022,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Restricted Stock Units","published_at":"2018-12-19T01:52:44.000Z","date":"2018-12-15","kind":"exercise","acquired":false,"shares":1733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On December 15, 2016, the reporting person was granted 13,866 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On December 15, 2016, the reporting person was granted 13,866 restricted stock units. 50% of the shares underlying these restricted stock units vested on May 7, 2018 upon the achievement of a specified commercial milestone. The other 50% of the shares underlying the restricted stock units vest in four equal annual installments beginning on December 15, 2017, subject to the reporting person's continuous service with the issuer as of the applicable vesting date."}],"balance_after":3467,"derivative":{"underlying":"Common Stock","underlying_shares":1733},"source":{"system":"sec-edgar","filing":"0001209191-18-063369","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919118063369/doc4.xml","form_type":"4"}},{"id":3727021,"issuer":{"id":5041,"kind":"organization","name":"Aclaris Therapeutics, Inc."},"owners":[{"id":35786,"kind":"person","name":"Ali-Jackson Kamil","position":1,"cik":"0001654337","reported_name":"Ali-Jackson Kamil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2018-12-19T01:52:44.000Z","date":"2018-12-15","kind":"tax_withholding","acquired":false,"shares":493,"price":7.31,"value":3603.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units being reported in this Form 4."}],"balance_after":78876,"source":{"system":"sec-edgar","filing":"0001209191-18-063369","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1654337/000120919118063369/doc4.xml","form_type":"4"}}],"next_cursor":"2018-12-19T01:52:44.000000Z,3727021"}